Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Transducer Mechanism: G Protein–Coupled Receptors

Transducer Mechanism: G Protein–Coupled Receptors

G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Optimization of colonoscope bedside precleaning protocol: an orthogonal experimental study.

Frontiers in cellular and infection microbiology·2026

Same author

Co-exposure to UV-328 and cadmium in radish: Interactive effects on uptake, translocation, and potential dietary risk.

Environmental pollution (Barking, Essex : 1987)·2026

Same author

Geographical patterns, sources, and ecological risks of short- and medium-chain chlorinated paraffins in mulching cultivated soils across China.

Journal of hazardous materials·2026

Same author

ROS-mediated membrane damage and antioxidant imbalance drive apple flesh browning during cold storage.

Frontiers in plant science·2025

Same author

Adaptation and Selection of Microbial Communities during Multiyear Biodegradable Plastic Mulching in Field Soils and Implications for Remediation.

Environmental science & technology·2025

Same author

Clinical outcomes of bowel preparation education strategies in colonoscopy: An evidence map of systematic reviews.

Medicine·2025

Same journal

NCP07: A potent ERα CBS-targeted degrader with dual-action against ESR1 mutations in breast cancer.

European journal of medicinal chemistry·2026

Same journal

Advances in selective inhibitors targeting the BD1 and BD2 domains of BET proteins.

European journal of medicinal chemistry·2026

Same journal

Development of potent BChE/Nrf2 modulators for Alzheimer's disease treatment via dual suppression of ferroptosis.

European journal of medicinal chemistry·2026

Same journal

Design, synthesis, and biological evaluation of HSP70-mediated HEMTACs as novel androgen receptor degraders.

European journal of medicinal chemistry·2026

Same journal

Design, synthesis, and anti-SARS-CoV-2 activity of vilazodone derivatives as METTL3 inhibitors.

European journal of medicinal chemistry·2026

Same journal

Fully synthetic arecoline and arecaidine vaccine candidates with α-Galactosylceramide as built-in adjuvant.

European journal of medicinal chemistry·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 24, 2025

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

Research progress on GPX4 targeted compounds.

Bingru Li¹, Keguang Cheng², Tzumei Wang¹

¹State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.

European Journal of Medicinal Chemistry

|June 5, 2024

Summary

This summary is machine-generated.

Targeting the glutathione peroxidase 4 (GPX4) pathway induces cancer cell death via ferroptosis. This review details compounds that directly target GPX4, offering new therapeutic strategies for cancer treatment.

More Related Videos

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

Related Experiment Videos

Last Updated: Jun 24, 2025

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

Area of Science:

Biochemistry
Oncology
Pharmacology

Background:

The System Xc-/glutathione/GPX4 pathway is crucial for cell survival.
GPX4 is a key regulator of ferroptosis, a form of programmed cell death.
Targeting GPX4 offers a novel strategy for cancer therapy.

Purpose of the Study:

To review compounds that directly target the GPX4 protein.
To explore inhibitors, activators, and degraders of GPX4.
To discuss combination therapies involving GPX4 targeting agents.

Main Methods:

Literature search for compounds targeting GPX4.
Categorization of compounds based on their mechanism of action (inhibitors, activators, degraders).
Analysis of current research on GPX4-targeting agents and combination therapies.

Main Results:

Several classes of compounds directly targeting GPX4 have been identified.
These include small molecule inhibitors, activators, and novel degraders (small molecule and chimeric).
Combination therapies show promise in enhancing anti-tumor effects.

Conclusions:

Direct targeting of GPX4 is a viable strategy for inducing ferroptosis in cancer cells.
Further research into GPX4-targeting compounds and combination therapies is warranted.
This approach holds potential for developing new cancer treatments.